Methods of treatment of CD123 overexpressing disorders

US10676533B2 · kind B2 · utility

Assignee

• Aptevo Research and Development LLC · US

Inventors

• Gabriela Hernandez-Hoyos · Seattle, US
• Elaine T. Sewell · Seattle, US
• Catherine J. McMahan · Seattle, US
• David Bienvenue · Seattle, US
• John W. Blankenship · Acton, US
• Danielle M. Mitchell · Seattle, US
• Peter Pavlik · Gaithersburg, US

Key dates

• Filing date: Mar 22, 2018
• Grant date: Jun 9, 2020
• Expiry date: Mar 22, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.